Cost-per-responder analysis of TAR-200 versus other Food and Drug Administration-approved novel and generic treatments among patients with Bacillus Calmette-Guérin–unresponsive, high-risk, non–muscle-invasive bladder cancer with carcinoma in situ in the United States

Stephen Williams; Sang Cho; Laura Morrison; Kruti Joshi; Dominic Pilon; Kayleen Gwyn; B. Libchaber; Gordon Wong; Francesca Lee; Urvi Desai; Mukul Singhal

doi:10.1080/13696998.2026.2651037

April 21, 2026Journal of Medical EconomicsOpen Access

Cost-per-responder analysis of TAR-200 versus other Food and Drug Administration-approved novel and generic treatments among patients with Bacillus Calmette-Guérin–unresponsive, high-risk, non–muscle-invasive bladder cancer with carcinoma in situ in the United States

View Full Paper

Ask AI

Bookmark

Share

Key Points

The research aims to compare the cost-effectiveness of TAR-200 with other approved treatments for high-risk bladder cancer patients.
Cost-per-responder analysis of patients receiving TAR-200 and other relevant treatments.
Evaluation of long-term complete response rates (CR) for treatments.
Comparison against FDA-approved options for BCG-unresponsive cases.
TAR-200 achieved the highest complete response (CR) rate lasting 12 months or more.
Significant cost savings per responder were observed with TAR-200 compared to other treatments.
Findings highlight TAR-200's potential as a cost-effective option for this patient population.

Abstract

TAR-200 demonstrated the highest proportion of patients achieving and sustaining CR for ≥12 months, yielding substantial cost savings per responder compared to other FDA-approved treatments for BCG-unresponsive HR-NMIBC with CIS.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Williams et al. (2026) studied this question.

synapsesocial.com/papers/69eb084f553a5433e34b3593 https://doi.org/10.1080/13696998.2026.2651037

View Full Paper

Ask AI

Bookmark

Share

Cost-per-responder analysis of TAR-200 versus other Food and Drug Administration-approved novel and generic treatments among patients with Bacillus Calmette-Guérin–unresponsive, high-risk, non–muscle-invasive bladder cancer with carcinoma in situ in the United States

Key Points

Abstract

Discussion

Cite This Study

Cost-per-responder analysis of TAR-200 versus other Food and Drug Administration-approved novel and generic treatments among patients with Bacillus Calmette-Guérin–unresponsive, high-risk, non–muscle-invasive bladder cancer with carcinoma in situ in the United States

Key Points

Abstract

Discussion

Cite This Study

Keep reading

Keep reading